Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Document › Details

Step Pharma SAS. (11/21/17). "Press Release: Step Pharma Completes €14.5 million Series A Financing with Additional New Investor". Paris.

Organisations Organisation Step Pharma SAS
  Organisation 2 Pontifax Ltd.
  Group Pontifax (Group)
Products Product CTPS1 inhibitor
  Product 2 venture capital
Index terms Index term Step Pharma–SEVERAL: investment, 201711 financing round Series A 2nd closing €8.6m bringing total round to €14.5m
  Index term 2 Step Pharma–Pontifax: investment, 201711 financing round Series A 2nd closing totalling €8.6m incl new investor Pontifax
Persons Person de Ribains, Geoffroy (AdBio Partners 202302– promoted to Managing Parnter joined AFB 2009 before Step Pharma + Biomunex)
  Person 2 Malier, Vanessa (Kurma 201412 Partner)

Proceeds to Support Advancement of First-in-class Immunomodulators for Autoimmune Diseases towards Clinical Studies

Step Pharma today announced the closing of a Series A financing totalling €14.5 million. Pontifax joined existing investors led by Kurma Partners, and including Bpifrance (Fonds Biothérapies Innovantes et Maladies Rares), Inserm Transfert Initiative, Idinvest, Sygnature Discovery and the Imagine Institute in an €8.6 million second closing of the round.

The additional proceeds will be used to advance the company’s novel class of oral immunomodulators targeting cytidine triphosphate synthase 1 (CTPS1) to clinical studies. CTPS1 is a novel target discovered at the Imagine Institute (Paris, France) in rare genetic disease patients exhibiting deficiency in this enzyme involved in CTP nucleotide production.

“There is a long, established history of using nucleotide synthesis inhibitors to treat autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis or psoriasis, but their clinical use is limited due to lack of tissue selectivity. Targeting CTPS1 should allow selective modulation of specific immune cell populations, such as T and B cells, without affecting other tissues, which should translate to better efficacy and an improved therapeutic index,” said Geoffroy de Ribains, CEO and co-founder of Step Pharma. “Our funding to date has enabled us to build a proprietary assay platform, discover first series of CTPS1 compounds and show initial proof of concept in vivo. With the continued support of our investors and new investor Pontifax, we will be able to advance our CTPS1 program into clinical testing.”

“Step Pharma is exploring a completely new paradigm for the treatment of autoimmune diseases. The rare combination of a clinically validated target, a novel mechanism of action, and a significant unmet medical need led us to create the company with the Imagine Institute and Sygnature Discovery, and we are excited to see the program progress. The ability of Step Pharma to attract Pontifax confirms the potential of this approach,” said Vanessa Malier of Kurma Partners.

Targeting CTPS1

Cytidine nucleotide triphosphate (CTP) is a precursor required for several key processes involved in cell division.

It originates from two sources: a salvage pathway and a de novo synthesis pathway that depends on several enzymes, including CTPS1.

Importantly, patients deficient in CTPS1 only exhibit certain immunodeficiencies without other clinical problems, strongly suggesting a predominant and key role of CTPS1 in selected immune cell populations. CTPS1 therefore represents a therapeutic target for a new class of highly selective immunomodulatory drugs.

About Step Pharma

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of autoimmune diseases. The company has identified several series of CTPS1 inhibitors, with the most advanced series currently undergoing lead optimization.

Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery based on the scientific discoveries of Dr Sylvain Latour’s laboratory and Prof. Alain Fischer (UMR1163 Inserm unit). Step Pharma is based in Paris, France. More information on the company can be found at

Record changed: 2024-03-30


Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Step Pharma SAS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top